Medtronic heads into its August 18 earnings date with a notable split on the Street — analysts cutting price targets yet maintaining positive ratings — while options traders are becoming more defensive than they have been all year.
The options story is the clearest tension this week. Put/call ratio has crept to 0.73, running well above its 20-day average of 0.62, putting the z-score at 1.4 standard deviations above the mean. That's not extreme, but it's a steady drift toward downside protection that has been building since late June when the PCR sat closer to 0.54. The 52-week high is 1.01, so there's room to move. This gradual defensive tilt is more consistent with pre-earnings hedging than a sudden fear trade — the next print is ten weeks out, but institutional calendars front-run that.
The lending market tells an almost entirely opposite story. Availability is essentially uncapped — borrow is about as loose as it gets, with over 1.2 billion shares available relative to roughly 18 million shorted. Short interest itself amounts to just 1.4% of the free float, up about 22% over the past month in share terms, but that's a move from a low base and doesn't signal a meaningful bear campaign. Cost to borrow is 0.49%, elevated roughly 11% on the week and 27% on the month — but the absolute level remains trivial. One data point worth noting: CTB briefly spiked to 7.6% on June 23 and to 4.3% on June 26, temporary dislocations that quickly reversed. No persistent squeeze pressure has built from those episodes. Positioning here looks relaxed rather than contested.
The Street's recent behaviour tells a more nuanced story. Bulls are holding their ratings but quietly lowering their targets. TD Cowen cut its target from $119 to $100 this week while keeping a Buy. Evercore ISI trimmed from $106 to $105. Further back, Wells Fargo shaved from $114 to $102, Bernstein from $112 to $97, and Leerink from $117 to $104 — all while maintaining positive ratings. Goldman Sachs and UBS sit on the sidelines with Neutral ratings and targets of $83 and $85 respectively, clustered right around the current price of $83.87. The mean target across the group is $97.73, implying roughly 16% upside from here — but that average has been in visible decline as bulls walk down their numbers. The bull case centres on Cardiac Ablation Solutions momentum, renal denervation expansion, and the planned Diabetes division separation. Bears point to TAVR volume uncertainty, inconsistent execution, and a competitive EP market that caps multiple expansion. Factor scores add texture: 90-day EPS momentum ranks in the 79th percentile of the universe and forward EPS growth ranks in the 94th, yet 30-day EPS momentum has faded to the 38th. The EV/EBITDA of 10.9x has drifted lower over the past month, consistent with the target cuts.
Insider activity adds a layer of caution. On June 4, CEO Geoff Martha sold 41,936 shares for roughly $3.5 million at $83.32. The same day, an Executive Vice President sold a further 6,800 shares and other executives followed with smaller disposals. The most recent transaction was an HR Director selling just over 3,100 shares on July 8 at $83.15 — close to today's price. The 90-day net insider position is technically a net award (share grants to executives in May offset the cash sales), but the pattern of consistent selling at current price levels is worth tracking into earnings season.
Among peers, SYK gained about 1% on the week while COO fell nearly 5% and RMD dropped close to 3%. ZBH was the strongest in the group, up 4.4%. MDT's 0.8% weekly gain puts it in the middle of the pack — neither leading nor lagging in a week of divergent readings across device names.
The earnings reaction history is genuinely notable. The most recent print, on June 3, drove an 11% one-day gain and an 8.8% five-day follow-through — a strong beat by any measure. The prior print in February delivered a 1% decline with a 2.8% five-day drift lower. With August 18 still over five weeks away, the key question ahead of that date is whether the gradual options drift toward puts broadens into something more pronounced, or whether a tightening consensus target range forces fresh buying as the stock approaches the lower end of analyst coverage.
See the live data behind this article on ORTEX.
Open MDT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
